Table 3

 Incremental costs, DALYs, and cost effectiveness ratios for antiretroviral monitoring study, Tororo and Busia Districts, Uganda, 2003-7

Cost ($)Incremental cost ($)DALYs incurredIncremental DALYs avertedICER: $ per DALY averted
Clinical606 260466.4
Clinical/CD4626 71820 458349.1117.3174
Clinical/CD4/viral load769 177142 458321.627.55181